Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A pasteurized therapeutic plasma.

M Burnouf-Radosevich1, T Burnouf, J J Huart

  • 1Centre de Transfusion Sanguine de Lille, France.

Infusionstherapie Und Transfusionsmedizin
|April 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delayed post-traumatic alopecia of the dorso-lumbar area following a road accident in a cat without pelvic fracture.

The Journal of small animal practice·2024
Same author

Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2021
Same author

Principles of haemophilia care: The Asia-Pacific perspective.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

International Forum on GMP-grade human platelet lysate for cell propagation: summary.

Vox sanguinis·2017
Same author

International Forum on GMP-grade human platelet lysate for cell propagation.

Vox sanguinis·2017
Same author

Global Forum of the World Federation of Hemophilia, September 26-27, 2005, Montreal, Quebec, Canada.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2017

This study demonstrates that pasteurization of pooled human plasma effectively inactivates viruses while preserving essential clotting factors and protease inhibitors. The process showed no adverse effects in animal models, ensuring safety and efficacy.

Area of Science:

  • Biotechnology
  • Virology
  • Hematology

Background:

  • Pooled human plasma is a critical therapeutic product.
  • Ensuring viral safety of plasma products is paramount.
  • Existing viral inactivation methods may affect plasma component efficacy.

Purpose of the Study:

  • To design and evaluate a pasteurization process for pooled human plasma.
  • To assess viral inactivation efficacy and recovery of biological properties.
  • To determine the safety profile of the pasteurized plasma.

Main Methods:

  • Pooled human plasma was subjected to liquid-state heating (60°C for 10 hours).
  • Clotting factor and protease inhibitor activities were measured.
  • Coagulation factor activation, aggregate formation, and thrombogenicity were assessed.

Related Experiment Videos

  • Virus kill studies were performed using lipid-enveloped and non-enveloped viruses, including HIV-1.

    • Main Results:

    • Over 80% recovery of clotting factors and protease inhibitors was achieved.
    • Good overall clotting activity was maintained with no detected coagulation factor activation.
    • No aggregates or adverse effects (toxicity, hypotension, heart rate variation, thrombogenicity) were observed in animal models.
    • High levels of inactivation were demonstrated for both lipid-enveloped and non-enveloped viruses, comparable to plasma derivatives.

    Conclusions:

    • Pasteurization of pooled human plasma is a viable method for viral inactivation.
    • The process effectively balances viral safety with the preservation of critical biological properties.
    • This method offers a safe and effective approach to enhance the safety of human plasma therapeutics.